Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of August 2021, with a specific transaction date of August 23, 2021. The report serves as a transaction notification regarding a Person Discharging Managerial Responsibilities (PDMR) rather than a periodic financial performance report.
Key Financial Metrics
The filing does not provide corporate financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to a specific insider transaction:
- Instrument: American Depositary Shares (ADSs)
- Transaction Type: Acquisition within an Executive Supplemental Savings Plan
- Price: $41.49 per ADS
- Volume: 1,205.300 ADSs
- Exchange: New York Stock Exchange (XNYS)
Material Changes
The filing does not disclose material changes to the company's financial position or operations compared to prior periods. It solely documents a single acquisition event by an executive.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a regulatory disclosure of an insider trade.
Key Facts for Investor Verification
- Executive Involved: Dr. H Barron, Chief Scientific Officer and President, R&D.
- Transaction Nature: The acquisition was made within Dr. Barron's GSK Executive Supplemental Savings Plan account, indicating a structured compensation or savings vehicle rather than an open-market discretionary purchase.
- Transaction Date: August 23, 2021.
- Reporting Date: August 25, 2021.